Marisa Wexler, MS,  senior science writer—

Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and other diseases. The deal with orelabrutinib’s developer, Innocare Pharma, includes rights to two other investigational therapies. Zenas will pay Innocare up to $100 million in cash and up to…

Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of multiple sclerosis (MS), with no new safety concerns reported. That’s according to new long-term data from the…

Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in people with primary progressive multiple sclerosis (PPMS). That’s according to top-line data from the Phase 3b GAVOTTE…

Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according to new Phase 4 trial data. The results come from the CLARIFY-MS (NCT03369665) and MAGNIFY-MS (NCT03364036)…

Treatment with equecabtagene autoleucel, known for short as eque-cel — Iaso Biotherapeutics‘ CAR T-cell therapy candidate for people with progressive forms of multiple sclerosis (MS) — was well tolerated and led to an easing of disability for five patients taking part in a Phase 1 clinical trial. The…

Combining the diabetes medication metformin and the antihistamine clemastine significantly increased myelin repair in people with relapsing-remitting multiple sclerosis (RRMS), according to results from a Phase 2 clinical trial. However, the effects were small, and participants showed no improvements in disability or visual function after six months of treatment.

Aerobic exercise may help promote myelin repair in some parts of the brain in people with multiple sclerosis (MS), according to a small study. Though the study included a small number of participants and followed them for a short period of time, the findings suggest that “supporting metabolic health…

Following the MIND diet, a program that focuses on brain health, may help reduce disability, ease fatigue, and improve quality of life for people with multiple sclerosis (MS), according to an analysis of data from a U.K. database. The diet, which combines aspects of the Mediterranean and the Dietary…

The new revisions to the McDonald criteria for multiple sclerosis (MS) —  a set of guidelines long used to diagnose the neurodegenerative condition — have increased the proportion of people who can be diagnosed with MS and also allow for earlier diagnoses. That’s according to a new analysis…

Note: This story was updated Sept. 23, 2025, to correct the generic name of Aubagio from tolebrutinib to teriflunomide. The U.S. Food and Drug Administration (FDA) has delayed by three months its decision on whether or not to approve Sanofi’s tolebrutinib as a treatment for multiple sclerosis (MS),…

Doctors will be able to diagnose multiple sclerosis (MS) faster and with greater accuracy — allowing patients to access treatment and support earlier — following an update to the McDonald criteria, the official guidelines used to diagnose the condition. The revision reflects advances in understanding the biology of…

Paramagnetic rim lesions (PRLs), which represent areas of damage in the brain and spinal cord with chronic active inflammation, are highly indicative of multiple sclerosis (MS) in people being evaluated for the disease, a new study reports. The findings support using this imaging biomarker as a useful tool for…

Immunic Therapeutics will receive a new U.S. patent covering its experimental therapy, vidofludimus calcium, and some related molecules in people with multiple sclerosis (MS). Titled “Treatment of multiple sclerosis comprising DHODH inhibitors,” the patent explicitly covers the use of the molecules in progressive types of MS, including primary…

In the U.S., nearly 4 out of 5 neurologists prescribing therapies for multiple sclerosis (MS) have received payments from pharmaceutical companies that market MS treatments, according to a new analysis. The findings indicate that neurologists who receive payments from a company are significantly more likely to prescribe that…

Targeting a protein called SOX6 could be an effective way to promote myelin repair in people with multiple sclerosis (MS), a study found. Researchers said the results point to a way for new therapies to treat the condition. The study found SOX6 could control the maturation of oligodendrocytes, the…

A ketogenic diet — which involves eating a very low amount of carbohydrates and replacing them with fat — may help ease fatigue, improve neurological function, and boost life quality in people with multiple sclerosis (MS), according to a new analysis. Researchers stressed that available data on the effects…

A new positron emission tomography (PET) tracer may help determine the extent of nerve fiber loss in multiple sclerosis (MS) lesions, something that can’t be identified with conventional MRI imaging, according to a new study. Researchers think the new imaging tech could help track the efficacy of experimental therapies…

Medications that can promote the repair of the myelin sheath — the protective coating around nerve cells in the body — may also help limit nerve damage in multiple sclerosis (MS), according to a new analysis of data from a small clinical trial testing an anticancer therapy called bexarotene…

A type of imaging finding called iron rim lesions are associated with more severe disability and a greater extent of brain damage in people with multiple sclerosis (MS), a new analysis suggests. This specific imaging finding may help guide discussions about individualized treatments for MS, the study’s researchers said.

Over the past three decades, the number of adults worldwide being diagnosed with multiple sclerosis (MS) has increased, but globally, rates of death related to complications of MS have declined, a new study shows. “The period from 1990 to 2021 has witnessed important shifts in the global landscape of…

Multiple sclerosis (MS) may increase the risk of developing Alzheimer’s disease, according to a new analysis of genetic data. The findings indicate genetic changes that influence the activity of immune T-cells may play a role in both MS and Alzheimer’s. The study, “Multiple sclerosis…

Fenebrutinib significantly reduced the occurrence of new brain lesions with active inflammation in people with relapsing multiple sclerosis (MS), a Phase 2 clinical trial found. In the open-label extension portion of the FENopta trial (NCT05119569), disease activity “remained very low” for nearly one year, researchers wrote, with 98%…

People with multiple sclerosis (MS) who are treated with formulations of botulinum toxin to manage spasticity generally report being satisfied with the treatment, a new study reports. The study examined the use of these formulations in people with spasticity due to a number of conditions, the most common…

A team of U.S. and Chinese researchers appears to have unlocked a novel way to stop T-cells from attacking the body in multiple sclerosis (MS) and other autoimmune diseases, according to the findings of a new study. An experimental therapy called BiTS, developed based on these new molecular insights,…

Anti-CD20 therapies, a type of treatment approved for multiple sclerosis (MS), alter the activity of several types of immune cells, including increasing the levels of certain anti-inflammatory immune cells. That’s according to the study “Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell…

A new imaging technology may help detect early signs of brain damage in people with multiple sclerosis (MS) that aren’t visible on conventional MRI scans, a recent study shows. The technology detects specific metabolic alterations in the brain by tracking certain metabolites and neurotransmitters — molecules that nerve…

More than 90% of relapsing-remitting multiple sclerosis (RRMS) patients who received Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium have not experienced confirmed disability worsening after nearly three years. That’s according to new data from the EMPhASIS Phase 2 clinical trial (NCT03846219) and its open-label extension (OLE)…

A CAR T-cell therapy from Iaso Biotherapeutics was tolerated well and led to marked improvements in disability for three people with progressive forms of multiple sclerosis (MS), according to early data from a Phase 1 clinical trial. After a single dose of equecabtagene autoleucel, patients saw rapid and…

In people with benign relapsing-remitting multiple sclerosis (RRMS) who have minimal disease activity, there is a loss of overall brain tissue but specific parts of the brain may grow to help compensate for the damage, a new study indicates. The study, “AI-driven MRI analysis reveals brain…

Hormone therapies used in gender-affirming care for transgender people may affect disease activity in multiple sclerosis (MS), a small new study reports, although its researchers cautioned that more research is are needed to more comprehensively assess its impact in MS. The study, “Gender-affirming interventions and prognosis…